View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 2, 2022

Rare eye disease gene therapy lacks efficacy in NIH-funded trial

Inflammatory eye ailment uveitis was the only treatment-related safety concern reported in the trial.

The US National Institutes of Health (NIH) has reported findings from a Phase I clinical trial where a gene therapy was found to be safe but lacked efficacy to treat Leber hereditary optic neuropathy (LHON), a degenerative retinal disease.

The gene therapy is intended to restore the ND4 gene’s function by injecting a viral vector (AAV2) that carries a normal gene into the left or right eyes of the patients. 

On injecting the viral vector, it deposits the gene into retinal ganglion cells where it merges into the nuclear DNA of the cell.

Sponsored partly by the NIH unit National Eye Institute, the trial enrolled 28 patients. 

In the trial, scientists analysed four therapeutic doses of the gene therapy, each having a different gene vector concentration. 

Subsequently, the team observed the trial subjects for up to three years for adverse events, variations in visual function, including acuity, and immune response to the therapy.

According to the findings, no substantial safety concerns were observed but the gene therapy failed to improve or decelerate vision loss even at the highest dose. 

Inflammatory eye ailment uveitis, which was more common with higher dosages, was the only treatment-related safety concern.

Furthermore, uveitis was reported in 71% of subjects who received the highest dose versus 15% for all other arms combined.

In a press statement NIH said: “Despite the therapy’s good safety profile, investigators were unable to show that it prevented vision loss. 

“Some participants’ vision improved in the injected eye, the fellow eye, or both. 

“Improvements are known to occur among people with LHON; however, participants with the least affected vision (20/40 or better) at the time of enrolment did not have vision preserved, losing about three lines of visual acuity, as measured on an eye chart, during the first 12 months after injection.”

Trial investigators noted that the gene therapy for LHON could offer visual benefits to some people, but the effect is at best modest. 

Based on these data, the investigators will not pursue further phases of clinical testing.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena